<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Yonsei Med J</journal-id><journal-id journal-id-type="iso-abbrev">Yonsei Med. J</journal-id><journal-id journal-id-type="publisher-id">YMJ</journal-id><journal-title-group><journal-title>Yonsei Medical Journal</journal-title></journal-title-group><issn pub-type="ppub">0513-5796</issn><issn pub-type="epub">1976-2437</issn><publisher><publisher-name>Yonsei University College of Medicine</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28540994</article-id><article-id pub-id-type="pmc">5447112</article-id><article-id pub-id-type="doi">10.3349/ymj.2017.58.4.800</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject><subj-group subj-group-type="subheading"><subject>Nephrology &#x00026; Urology</subject></subj-group></subj-group></article-categories><title-group><article-title>Clinical Efficacy and Safety of Naftopidil Treatment for Patients with Benign Prostatic Hyperplasia and Hypertension: A Prospective, Open-Label Study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Chung</surname><given-names>Mun Su</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Yoon</surname><given-names>Byung Il</given-names></name><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Lee</surname><given-names>Seung Hwan</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Urology, Catholic Kwandong University, International St. Mary's Hospital, Incheon, Korea.</aff><aff id="A2"><label>2</label>Department of Urology, Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.</aff><author-notes><corresp>
Corresponding author: Dr. Seung Hwan Lee, Department of Urology, Urological Science Institute, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea. Tel: 82-2-2019-3470, Fax: 82-2-3462-8887, <email>leeseh@yuhs.ac</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>18</day><month>5</month><year>2017</year></pub-date><volume>58</volume><issue>4</issue><fpage>800</fpage><lpage>806</lpage><history><date date-type="received"><day>24</day><month>2</month><year>2017</year></date><date date-type="rev-recd"><day>05</day><month>4</month><year>2017</year></date><date date-type="accepted"><day>06</day><month>4</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; Copyright: Yonsei University College of Medicine 2017</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Purpose</title><p>To investigate the efficacy and safety of naftopidil for benign prostatic hyperplasia (BPH) patients, mainly focusing on changes in blood pressure (BP).</p></sec><sec><title>Materials and Methods</title><p>Of a total of 118 patients, 90 normotensive (NT) and 28 hypertensive (HT) patients were randomly assigned to be treated with naftopidil 50 mg or 75 mg for 12 weeks, once-daily. Safety and efficacy were assessed by analyzing changes from baseline in systolic/diastolic BP and total International Prostate Symptom Score (IPSS) at 4 and 12 weeks. Adverse events (AEs), obstructive/irritative subscores, quality of life (QoL) score, maximum urinary flow rate (Qmax), and benefit, satisfaction with treatment, and willingness to continue treatment (BSW) questionnaire were also analyzed.</p></sec><sec><title>Results</title><p>Naftopidil treatment decreased mean systolic BP by 18.7 mm Hg for the HT 50 mg group (<italic>p</italic>&#x0003c;0.001) and by 18.3 mm Hg for the HT 75 mg group (<italic>p</italic>&#x0003c;0.001) and mean diastolic BP by 17.5 mm Hg for the HT 50 mg group (<italic>p</italic>&#x0003c;0.001) and by 14.7 mm Hg for the HT 75 mg group (<italic>p</italic>=0.022). In the NT groups (both naftopidil 50 mg and 75 mg), naftopidil elicited no significant changes in BP from baseline values. After 12 weeks, naftopidil 50 and 75 mg groups showed significant improvements in IPSS scores (total, obstructive/irritative subscores, QoL score) and Qmax from baseline. AEs were reported in 7.8% (50 mg group) and 2.9% (75 mg group) of patients. In both the 50 mg and 75 mg groups, &#x0003e;86% of all patients agreed to continue their current medications.</p></sec><sec><title>Conclusion</title><p>Our results suggest that naftopidil treatment in BPH patients with hypertension allows for optimal management of BP within the normal range.</p></sec></abstract><kwd-group><kwd>&#x003b1;-adrenoceptor antagonists</kwd><kwd>BPH</kwd><kwd>hypertension</kwd><kwd>naftopidil</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution>Dong-A Pharmaceutical Co., Ltd.</institution></institution-wrap></funding-source></award-group></funding-group></article-meta></front><body><sec sec-type="intro"><title>INTRODUCTION</title><p>Benign prostatic hyperplasia (BPH) is the most common urological disorder in older men, and its incidence is expected to rise with increasing life expectancy. Hypertension is also a common disease in older age adults. Studies suggest that age-related increases in sympathetic noradrenergic activity may be a common pathophysiologic component in BPH and hypertension.<xref rid="B1" ref-type="bibr">1</xref><xref rid="B2" ref-type="bibr">2</xref><xref rid="B3" ref-type="bibr">3</xref><xref rid="B4" ref-type="bibr">4</xref> Even disregarding the possibility of a common pathology, it is estimated that at least one in four men aged &#x0003e;60 years could have concomitant BPH and hypertension.<xref rid="B4" ref-type="bibr">4</xref><xref rid="B5" ref-type="bibr">5</xref></p><p>Selective &#x003b1;1-adrenoceptor (AR) antagonists are well known to be an effective, non-invasive treatment option for patients with BPH. Lower urinary tract symptoms (LUTS) can be improved by reduction of urethral pressure and prostatic smooth muscle tone by blocking the motor sympathetic adrenergic nerve supply to the prostrate. These agents are currently considered as first-line medical therapy for BPH patients,<xref rid="B5" ref-type="bibr">5</xref><xref rid="B6" ref-type="bibr">6</xref><xref rid="B7" ref-type="bibr">7</xref> and numerous studies regarding their efficacy and tolerability have been reported.</p><p>Of these agents, naftopidil is an &#x003b1;1-AR antagonist that has high selectivity for the &#x003b1;1D subtype, showing 3- and 17-fold higher affinity for this subtype than for &#x003b1;1A and &#x003b1;1B subtypes, respectively.<xref rid="B8" ref-type="bibr">8</xref><xref rid="B9" ref-type="bibr">9</xref> Although several clinical trials <xref rid="B9" ref-type="bibr">9</xref><xref rid="B10" ref-type="bibr">10</xref><xref rid="B11" ref-type="bibr">11</xref><xref rid="B12" ref-type="bibr">12</xref> demonstrating the efficacy of this drug for BPH patients have been reported, there are few reports of the cardiovascular responses associated with this drug during BPH treatment. Here, we aimed to determine the efficacy and safety of naftopidil for BPH/LUTS patients, focusing on 1) changes in blood pressure (BP) and 2) patient satisfaction and compliance.</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Study design</title><p>This study was designed as a prospective, open-label study to determine the efficacy and safety of naftopidil (Flivas, Dong-A Pharmaceutical Co., Ltd., Seoul, Korea) at a single center (Yonsei University Health System, Severance Hospital, Seoul, Korea). The study protocol was approved by our Institutional Review Board (IRB approval No. 4-2014-0503, Yonsei University Health System). Patients provided written consent to participate in the study after having received an explanation of the protocol, including awareness of possible side effects.</p><p>Based on an assumption of a mean improvement in total international prostate symptom score (IPSS) from baseline of 3.0, a standard deviation of 5.3, and the assumption that 20% of patients will not be valid for inclusion in the per-protocol population, a sample size of at least 120 patients was required to obtain a power of 90%, with type 1 error of 0.05 (for a two-sided test). Results are reported for the intention to treat (ITT) population (all patients with a baseline BP and IPSS assessment and at least one valid post-baseline BP and IPSS assessment).</p><p>The enrolled patients suffered from LUTS and were considered fit for &#x003b1;1-AR antagonist treatment based on the decision of our physician. Patients who met the inclusion criteria were assigned into the normotensive (NT) group (defined as diastolic BP &#x0003c;90 mm Hg in a sitting position) or hypertensive (HT) group (diastolic BP &#x02265;90 mm Hg in a sitting position) and then randomly assigned by computer-generated random numbers into the naftopidil 50 mg group or 75 mg group for 12-week, oncedaily treatment.</p><p>BP was measured according to previous published guidelines:<xref rid="B13" ref-type="bibr">13</xref><xref rid="B14" ref-type="bibr">14</xref> 1) patients were seated quietly for at least 5 minutes in a chair with their feet on the floor and arms at the level of the heart, 2) at least two measurements at 1&#x02013;2 minute intervals were made, 3) we used a standard bladder (12&#x02013;13&#x000d7;35 cm), a larger one for big arms, and 4) we deflated the cuff slowly (2 mm Hg/sec). Patient visits occurred at study entry and after 4 weeks and 12 weeks of treatment. Adverse events (AEs) were defined as symptoms that required discontinuation or change of the current medication.</p></sec><sec><title>Study population</title><p>The inclusion criteria included male ambulatory patients over 50 years of age with LUTS (total IPSS greater than 8). Patients with the following conditions were excluded: allergic drug reaction to &#x003b1;1-AR antagonists, orthostatic hypotension, a history of prostate-related surgery (open or endoscopic), suspicious prostate malignant condition on digital rectal examination and/or prostate-specific antigen (PSA) &#x0003e;10 ng/mL, a history of recurrent urinary tract infection or bladder stones, renal impairment (creatinine clearance rate &#x0003c;30 mL/min), severe hepatic disorders, the use of anticholinergic or cholinergic agents, the use of other &#x003b1;1-AR antagonists (tamsulosin, silodosin, alfuzosin, doxazocin, terazocin) within the previous 4 weeks, or the use of 5-reductase inhibitors or antiandrogens within the previous 3 months. Patients who were currently receiving or were planning to take any &#x003b1;-receptor agonists or &#x003b2;-receptor antagonists were also excluded.</p></sec><sec><title>Study end-points and assessments</title><p>The primary end-point of this study was to determine the safety and efficacy of naftopidil 50 and 75 mg treatment. This measure was assessed by analyzing changes from baseline in systolic/diastolic BP and total IPSS at 4 and 12 weeks. Secondary aims were to analyze 1) AEs; 2) improvement in IPSS obstructive/irritative subscores, IPSS quality of life (QoL) score, and maximum urinary flow rate (Qmax); and 3) benefit, satisfaction with treatment, and willingness to continue treatment (BSW) questionnaire with naftopidil 50 and 75 mg treatment at 4 and 12 weeks. The safety population was all patients who were randomized and who received at least one dose of study medication.</p></sec><sec><title>Statistical analysis</title><p>The two-sample t-test and Wilcoxon rank sum test were conducted to analyze continuous variables, and the chi-square test was used to analyze categorical variables. Comparison of the efficacy variables was performed using an RM-ANOVA model with baseline values of the response variable as covariates for absolute change in IPSS from baseline. For efficacy evaluations, the last observation carried forward was applied to analyze the ITT population. Statistical analysis was performed with Prism software (version 5.00; GraphPad Instat, San Diego, CA, USA). Results were considered significant at <italic>p</italic>&#x0003c;0.05.</p></sec></sec><sec sec-type="results"><title>RESULTS</title><sec><title>Study design</title><p>A total of 120 patients were screened and 118 were enrolled in this study (<xref ref-type="fig" rid="F1">Fig. 1</xref>). Of these, 90 NT patients and 28 HT patients were randomized to receive naftopidil 50 mg or naftopidil 75 mg (group 1, NT 50 mg naftopidil; group 2, NT 75 mg naftopidil; group 3, HT 50 mg naftopidil, group 4, HT 75 mg naftopidil). In the NT group, 83 patients completed the study. The main reason for study discontinuation was AEs (6 patients, 6.6%), and one patient withdrew informed consent. In the HT group, 27 patients completed the study, and one discontinued because of loss during follow-up.</p></sec><sec><title>Patient demographics and characteristics</title><p>Baseline demographics and characteristics for all patients in the ITT population are shown in <xref ref-type="table" rid="T1">Table 1</xref>. There were no significant differences between the four treatment groups in regards to age, height, weight, prostate volume, level of PSA, total IPSS scores, IPSS obstructive or irritative subscore, QoL due to urinary symptoms, Qmax, or post-void residual urine volume. Systolic and diastolic BP were significantly different between groups 1 and 2 and groups 3 and 4 (<italic>p</italic>&#x0003c;0.001).</p></sec><sec><title>Influence on BP</title><p>Naftopidil treatment decreased the mean systolic BP by 18.7 mm Hg for group 3 (<italic>p</italic>&#x0003c;0.001) and by 18.3 mm Hg for group 4 (<italic>p</italic>&#x0003c;0.001) and the mean diastolic BP by 17.5 mm Hg for group 3 (<italic>p</italic>&#x0003c;0.001) and by 14.7 mm Hg for group 4 (<italic>p</italic>=0.022) (<xref ref-type="fig" rid="F2">Fig. 2</xref>). However, in the NT groups (both naftopidil 50 and 75 mg), naftopidil caused no significant changes in BP from baseline values. After adjusting for age, significant changes in mean systolic and diastolic BPs from baseline values were found in group 3 and group 4 vs. group 1 and group 2 (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p></sec><sec><title>Efficacy</title><p>The efficacy of naftopidil 50 and 75 mg on LUTS is summarized in <xref ref-type="fig" rid="F3">Fig. 3</xref>. After 12 weeks of treatment, both groups showed significant improvements from baseline in total IPSS score (<italic>p</italic>&#x0003c;0.001). For both obstructive and irritative subscores, there were significant improvements from baseline to the final visit for both 50 and 75 mg doses (<italic>p</italic>&#x0003c;0.001 and <italic>p</italic>=0.028, respectively). Also, IPSS QoL scores after treatment with both drug doses improved significantly at 12 weeks (<italic>p</italic>&#x0003c;0.001). Both groups showed significant improvement in Qmax from baseline at 12 weeks (<italic>p</italic>=0.034 in naftopidil 50 mg group and <italic>p</italic>&#x0003c;0.001 in 75 mg group).</p></sec><sec><title>Safety</title><p>AEs were reported in four of 51 patients (7.8%) receiving naftopidil 50 mg and in two of 67 (2.9%) receiving naftopidil 75 mg (<xref ref-type="table" rid="T2">Table 2</xref>). No syncope was reported for either group. None of the patients reported retrograde ejaculation. Most AEs were mild or moderate in severity.</p></sec><sec><title>Satisfaction and compliance</title><p>After completion of 12 weeks of treatment with naftopidil, satisfaction and compliance with this drug were assessed using the BSW questionnaire (<xref ref-type="table" rid="T3">Table 3</xref>). In both the 50 and 75 mg group, &#x0003e;76.6% of all patients felt they benefited from the treatment and were satisfied therewith. Moreover, 95.7% of patients in the naftopidil 50 mg group and 86% in the 75 mg group agreed to continue their current medications. The reasons for discontinuation were gastrointestinal trouble (n=2 in naftopidil 50 mg group and n=5 in 75 mg group) and dizziness (n=4 in naftopidil 75 mg group).</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Considering the high incidence of patients with concomitant BPH and hypertension, physicians are concerned about the influence of BP changes during &#x003b1;1-AR antagonist treatment in such cases. Many studies regarding BP change in patients with BPH/hypertension treated with &#x003b1;1-AR antagonist have been reported. In 1995, Kirby<xref rid="B15" ref-type="bibr">15</xref> reported that 12 weeks of treatment with doxazosin resulted in significant reductions in BP in HT patients, whereas minimal reductions were found in placebo-treated patients. Kaplan, et al.<xref rid="B16" ref-type="bibr">16</xref> showed that doxazosin treatment did not cause a clinically significant BP change in NT patients. Chung and Hong<xref rid="B5" ref-type="bibr">5</xref> reported that doxazosin gastrointestinal therapeutic system (GITS) treatment for 1 year resulted in a significantly greater reduction in BP in HT patients, compared with NT patients. Lee, et al.<xref rid="B3" ref-type="bibr">3</xref> compared the BP-lowering effect of &#x003b1;1-AR antagonists in patients with or without concomitant antihypertensive drug treatment and reported that doxazosin GITS treatment resulted in optimal management of BP within the normal range, especially in baseline HT BP patients, irrespective of concomitant antihypertensive medication. Fawzy, et al.<xref rid="B4" ref-type="bibr">4</xref> demonstrated that doxazosin is especially beneficial in the treatment of concomitant BPH and hypertension. Considering that older men might already be taking multiple medications for other diseases, the use of a single drug for two diseases might be valuable.</p><p>The majority of these reports, however, concern doxazosin treatment. Because doxazosin is a non-uroselective &#x003b1;1-AR antagonist, its influence on BP might be understandable. However, there are few reports on BP change with naftopidil, an &#x003b1;1-AR antagonist that has a high affinity for the &#x003b1;1D subtype. In our institution, we experienced stabilization of BP during naftopidil treatment for BPH/LUTS. From our experience, we think that this additional benefit of BPH medication results in increased satisfaction and compliance of the patients with this drug. Therefore, we aimed to further investigate the influence of naftopidil, mainly focusing on the cardiovascular aspects (i.e., BP change), as well as its efficacy for LUTS and patient satisfaction/compliance.</p><p>In terms of BP change with uroselective &#x003b1;1-AR antagonist in HT patients, a previous report<xref rid="B3" ref-type="bibr">3</xref> showed that treatment with tamsulosin and alfuzosin resulted in only a slight reduction in systolic BP. However, in the present study, treatment with naftopidil 50 mg or 75 mg resulted in significant reductions in systolic and diastolic BP in baseline HT patients (<xref ref-type="fig" rid="F2">Fig. 2</xref>). In NT patients, systolic and diastolic BP were optimally managed with naftopidil.</p><p>The pharmacological mechanism of the BP-lowering effect associated with naftopidil could be related to calcium-channel-blocking activity. In 1991, Himmel, et al.<xref rid="B17" ref-type="bibr">17</xref> reported that naftopidil could act as a weak ligand for L-type calcium channels, leading to ca<sup>2+</sup> antagonistic effects. Similarly, several reports<xref rid="B18" ref-type="bibr">18</xref><xref rid="B19" ref-type="bibr">19</xref> demonstrated that naftopidil has both &#x003b1;-AR and calcium-blocking activity. We think further studies are needed to address this.</p><p>In the present study, results from the BSW questionnaire suggested that treatment with naftopidil also shows increased satisfaction and compliance with this drug among patients. In both the 50 and 75 mg groups, the majority of patients felt benefit with satisfaction and agreed to continue this drug (<xref ref-type="table" rid="T3">Table 3</xref>).</p><p>Analysis of the BP-lowering effect of naftopidil with or without concomitant antihypertensive medication revealed significant reductions in systolic and diastolic BP in baseline HT patients, irrespective of concomitant antihypertensive medication (data not shown). These results are consistent with the previous report by Lee, et al.<xref rid="B3" ref-type="bibr">3</xref> Regarding efficacy, the overall efficacy of BPH treatment with naftopidil for 12 weeks in the present study was similar to the results of a previous study.<xref rid="B9" ref-type="bibr">9</xref> When comparing naftopidil 50 mg vs. 75 mg groups, overall efficacy parameters were superior with the higher dose (75 mg), although the differences were not statistically significant (<xref ref-type="fig" rid="F3">Fig. 3</xref>). In addition, several studies <xref rid="B10" ref-type="bibr">10</xref><xref rid="B20" ref-type="bibr">20</xref><xref rid="B21" ref-type="bibr">21</xref><xref rid="B22" ref-type="bibr">22</xref><xref rid="B23" ref-type="bibr">23</xref> on naftopidil treatment reported improvement of irritative symptoms with this drug. Nishino, et al.<xref rid="B10" ref-type="bibr">10</xref> reported that naftopidil was better than tamsulosin for nocturia. Other series <xref rid="B24" ref-type="bibr">24</xref><xref rid="B25" ref-type="bibr">25</xref><xref rid="B26" ref-type="bibr">26</xref> suggested that upregulation of &#x003b1;1D-AR in the bladder contributes to the storage symptoms observed in bladder outlet obstruction and that targeting the &#x003b1;1D-AR with naftopidil may provide a new therapeutic approach for controlling storage symptoms in patients with BPH. However, in our study, we noted little difference in improvement in storage symptoms, compared with other &#x003b1;1-AR antagonists.</p><p>There are several limitation in our study. First, the study included a relatively small number of patients and a short period of follow-up. Second, we measured BP only with the patient in the seated position. We acknowledge the methodological flaw of not measuring BP in a supine position, in addition to the sitting position, to rule out any orthostatic hypotension that might be present. Finally, we were unable to determine why the naftopidil treatment lowered BP in HT patients, compared with NT patients, and future studies to elucidate the underlying mechanism will be needed. However, we think that our results provide adequate preliminary data to support the additional benefit (optimal management of BP within the normal range) of naftopidil treatment in BPH/LUTS patients.</p></sec></body><back><ack><title>ACKNOWLEDGEMENTS</title><p>This study was sponsored by Dong-A Pharmaceutical Co., Ltd., Seoul, Korea.</p></ack><fn-group><fn fn-type="COI-statement"><p>The authors have no financial conflicts of interest.</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Boyle</surname><given-names>P</given-names></name><name><surname>Napalkov</surname><given-names>P</given-names></name></person-group><article-title>The epidemiology of benign prostatic hyperplasia and observations on concomitant hypertension</article-title><source>Scand J Urol Nephrol Suppl</source><year>1995</year><volume>168</volume><fpage>7</fpage><lpage>12</lpage><pub-id pub-id-type="pmid">7541551</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parsons</surname><given-names>JK</given-names></name></person-group><article-title>Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems</article-title><source>J Urol</source><year>2007</year><volume>178</volume><fpage>395</fpage><lpage>401</lpage><pub-id pub-id-type="pmid">17561143</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SH</given-names></name><name><surname>Park</surname><given-names>KK</given-names></name><name><surname>Mah</surname><given-names>SY</given-names></name><name><surname>Chung</surname><given-names>BH</given-names></name></person-group><article-title>Effects of &#x003b1;-blocker &#x02018;add on&#x02019; treatment on blood pressure in symptomatic BPH with or without concomitant hypertension</article-title><source>Prostate Cancer Prostatic Dis</source><year>2010</year><volume>13</volume><fpage>333</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">20567256</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fawzy</surname><given-names>A</given-names></name><name><surname>Hendry</surname><given-names>A</given-names></name><name><surname>Cook</surname><given-names>E</given-names></name><name><surname>Gonzalez</surname><given-names>F</given-names></name></person-group><article-title>Long-term (4 year) efficacy and tolerability of doxazosin for the treatment of concurrent benign prostatic hyperplasia and hypertension</article-title><source>Int J Urol</source><year>1999</year><volume>6</volume><fpage>346</fpage><lpage>354</lpage><pub-id pub-id-type="pmid">10445304</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>BH</given-names></name><name><surname>Hong</surname><given-names>SJ</given-names></name></person-group><article-title>Long-term follow-up study to evaluate the efficacy and safety of the doxazosin gastrointestinal therapeutic system in patients with benign prostatic hyperplasia with or without concomitant hypertension</article-title><source>BJU Int</source><year>2006</year><volume>97</volume><fpage>90</fpage><lpage>95</lpage><pub-id pub-id-type="pmid">16336335</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McConnell</surname><given-names>JD</given-names></name><name><surname>Roehrborn</surname><given-names>CG</given-names></name><name><surname>Bautista</surname><given-names>OM</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names><suffix>Jr</suffix></name><name><surname>Dixon</surname><given-names>CM</given-names></name><name><surname>Kusek</surname><given-names>JW</given-names></name><etal/></person-group><article-title>The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>2387</fpage><lpage>2398</lpage><pub-id pub-id-type="pmid">14681504</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>RS</given-names></name><name><surname>Roehrborn</surname><given-names>C</given-names></name><name><surname>Boyle</surname><given-names>P</given-names></name><name><surname>Bartsch</surname><given-names>G</given-names></name><name><surname>Jardin</surname><given-names>A</given-names></name><name><surname>Cary</surname><given-names>MM</given-names></name><etal/></person-group><article-title>Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial</article-title><source>Urology</source><year>2003</year><volume>61</volume><fpage>119</fpage><lpage>126</lpage><pub-id pub-id-type="pmid">12559281</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takei</surname><given-names>R</given-names></name><name><surname>Ikegaki</surname><given-names>I</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Tsujimoto</surname><given-names>G</given-names></name><name><surname>Asano</surname><given-names>T</given-names></name></person-group><article-title>Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors</article-title><source>Jpn J Pharmacol</source><year>1999</year><volume>79</volume><fpage>447</fpage><lpage>454</lpage><pub-id pub-id-type="pmid">10361884</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gotoh</surname><given-names>M</given-names></name><name><surname>Kamihira</surname><given-names>O</given-names></name><name><surname>Kinukawa</surname><given-names>T</given-names></name><name><surname>Ono</surname><given-names>Y</given-names></name><name><surname>Ohshima</surname><given-names>S</given-names></name><name><surname>Origasa</surname><given-names>H</given-names></name></person-group><collab>Tokai Urological Clinical Trial Group</collab><article-title>Comparison of tamsulosin and naftopidil for efficacy and safety in the treatment of benign prostatic hyperplasia: a randomized controlled trial</article-title><source>BJU Int</source><year>2005</year><volume>96</volume><fpage>581</fpage><lpage>586</lpage><pub-id pub-id-type="pmid">16104914</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nishino</surname><given-names>Y</given-names></name><name><surname>Masue</surname><given-names>T</given-names></name><name><surname>Miwa</surname><given-names>K</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Ishihara</surname><given-names>S</given-names></name><name><surname>Deguchi</surname><given-names>T</given-names></name></person-group><article-title>Comparison of two alpha1-adrenoceptor antagonists, naftopidil and tamsulosin hydrochloride, in the treatment of lower urinary tract symptoms with benign prostatic hyperplasia: a randomized crossover study</article-title><source>BJU Int</source><year>2006</year><volume>97</volume><fpage>747</fpage><lpage>751</lpage><pub-id pub-id-type="pmid">16536766</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perumal</surname><given-names>C</given-names></name><name><surname>Chowdhury</surname><given-names>PS</given-names></name><name><surname>Ananthakrishnan</surname><given-names>N</given-names></name><name><surname>Nayak</surname><given-names>P</given-names></name><name><surname>Gurumurthy</surname><given-names>S</given-names></name></person-group><article-title>A comparison of the efficacy of naftopidil and tamsulosin hydrochloride in medical treatment of benign prostatic enlargement</article-title><source>Urol Ann</source><year>2015</year><volume>7</volume><fpage>74</fpage><lpage>78</lpage><pub-id pub-id-type="pmid">25657550</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Komiya</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Awa</surname><given-names>Y</given-names></name><name><surname>Egoshi</surname><given-names>K</given-names></name><name><surname>Onishi</surname><given-names>T</given-names></name><name><surname>Nakatsu</surname><given-names>H</given-names></name><etal/></person-group><article-title>Clinical effect of naftopidil on the quality of life of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective study</article-title><source>Int J Urol</source><year>2010</year><volume>17</volume><fpage>555</fpage><lpage>562</lpage><pub-id pub-id-type="pmid">20370847</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chobanian</surname><given-names>AV</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Black</surname><given-names>HR</given-names></name><name><surname>Cushman</surname><given-names>WC</given-names></name><name><surname>Green</surname><given-names>LA</given-names></name><name><surname>Izzo</surname><given-names>JL</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure</article-title><source>Hypertension</source><year>2003</year><volume>42</volume><fpage>1206</fpage><lpage>1252</lpage><pub-id pub-id-type="pmid">14656957</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cifkova</surname><given-names>R</given-names></name><name><surname>Erdine</surname><given-names>S</given-names></name><name><surname>Fagard</surname><given-names>R</given-names></name><name><surname>Farsang</surname><given-names>C</given-names></name><name><surname>Heagerty</surname><given-names>AM</given-names></name><name><surname>Kiowski</surname><given-names>W</given-names></name><etal/></person-group><article-title>Practice guidelines for primary care physicians: 2003 ESH/ESC hypertension guidelines</article-title><source>J Hypertens</source><year>2003</year><volume>21</volume><fpage>1779</fpage><lpage>1786</lpage><pub-id pub-id-type="pmid">14508180</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kirby</surname><given-names>RS</given-names></name></person-group><article-title>Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men</article-title><source>Urology</source><year>1995</year><volume>46</volume><fpage>182</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">7542819</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>SA</given-names></name><name><surname>Meade-D'Alisera</surname><given-names>P</given-names></name><name><surname>Qui&#x000f1;ones</surname><given-names>S</given-names></name><name><surname>Soldo</surname><given-names>KA</given-names></name></person-group><article-title>Doxazosin in physiologically and pharmacologically normotensive men with benign prostatic hyperplasia</article-title><source>Urology</source><year>1995</year><volume>46</volume><fpage>512</fpage><lpage>517</lpage><pub-id pub-id-type="pmid">7571220</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Himmel</surname><given-names>HM</given-names></name><name><surname>Glossmann</surname><given-names>H</given-names></name><name><surname>Ravens</surname><given-names>U</given-names></name></person-group><article-title>Naftopidil, a new alpha-adrenoceptor blocking agent with calcium antagonistic properties: characterization of Ca2+ antagonistic effects</article-title><source>J Cardiovasc Pharmacol</source><year>1991</year><volume>17</volume><fpage>213</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">1709225</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sponer</surname><given-names>G</given-names></name><name><surname>Borbe</surname><given-names>HO</given-names></name><name><surname>M&#x000fc;ller-Beckmann</surname><given-names>B</given-names></name><name><surname>Freud</surname><given-names>P</given-names></name><name><surname>Jakob</surname><given-names>B</given-names></name></person-group><article-title>Naftopidil, a new adrenoceptor blocking agent with Ca(2+)-antagonistic properties: interaction with adrenoceptors</article-title><source>J Cardiovasc Pharmacol</source><year>1992</year><volume>20</volume><fpage>1006</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">1282583</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grundke</surname><given-names>M</given-names></name><name><surname>Himmel</surname><given-names>HM</given-names></name><name><surname>Wettwer</surname><given-names>E</given-names></name><name><surname>Borbe</surname><given-names>HO</given-names></name><name><surname>Ravens</surname><given-names>U</given-names></name></person-group><article-title>Characterization of Ca(2+)-antagonistic effects of three metabolites of the new antihypertensive agent naftopidil, (naphthyl)hydroxy-naftopidil, (phenyl)hydroxy-naftopidil, and O-desmethyl-naftopidil</article-title><source>J Cardiovasc Pharmacol</source><year>1991</year><volume>18</volume><fpage>918</fpage><lpage>925</lpage><pub-id pub-id-type="pmid">1725907</pub-id></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugaya</surname><given-names>K</given-names></name><name><surname>Nishijima</surname><given-names>S</given-names></name><name><surname>Miyazato</surname><given-names>M</given-names></name><name><surname>Ashitomi</surname><given-names>K</given-names></name><name><surname>Hatano</surname><given-names>T</given-names></name><name><surname>Ogawa</surname><given-names>Y</given-names></name></person-group><article-title>Effects of intrathecal injection of tamsulosin and naftopidil, alpha-1A and -1D adrenergic receptor antagonists, on bladder activity in rats</article-title><source>Neurosci Lett</source><year>2002</year><volume>328</volume><fpage>74</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">12123863</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Utsunomiya</surname><given-names>N</given-names></name><name><surname>Matsumoto</surname><given-names>K</given-names></name><name><surname>Tsunemori</surname><given-names>H</given-names></name><name><surname>Muguruma</surname><given-names>K</given-names></name><name><surname>Kawakita</surname><given-names>M</given-names></name><name><surname>Kamiyama</surname><given-names>Y</given-names></name><etal/></person-group><article-title>[A crossover comparison study on lower urinary tract symptoms with overactive bladder secondary to benign prostatic hyperplasia: naftopidil versus tamsulosin with solifenacin]</article-title><source>Hinyokika Kiyo</source><year>2016</year><volume>62</volume><fpage>341</fpage><lpage>347</lpage><pub-id pub-id-type="pmid">27569351</pub-id></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakai</surname><given-names>H</given-names></name><name><surname>Igawa</surname><given-names>T</given-names></name><name><surname>Onita</surname><given-names>T</given-names></name><name><surname>Furukawa</surname><given-names>M</given-names></name><name><surname>Hakariya</surname><given-names>T</given-names></name><name><surname>Hayashi</surname><given-names>M</given-names></name><etal/></person-group><article-title>[Efficacy of naftopidil in patients with overactive bladder associated with benign prostatic hyperplasia: prospective randomized controlled study to compare differences in efficacy between morning and evening medication]</article-title><source>Hinyokika Kiyo</source><year>2011</year><volume>57</volume><fpage>7</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">21304253</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oh-oka</surname><given-names>H</given-names></name></person-group><article-title>Effect of naftopidil on nocturia after failure of tamsulosin</article-title><source>Urology</source><year>2008</year><volume>72</volume><fpage>1051</fpage><lpage>1055</lpage><pub-id pub-id-type="pmid">18817955</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hampel</surname><given-names>C</given-names></name><name><surname>Dolber</surname><given-names>PC</given-names></name><name><surname>Smith</surname><given-names>MP</given-names></name><name><surname>Savic</surname><given-names>SL</given-names></name><name><surname>Th roff</surname><given-names>JW</given-names></name><name><surname>Thor</surname><given-names>KB</given-names></name><etal/></person-group><article-title>Modulation of bladder alpha1-adrenergic receptor subtype expression by bladder outlet obstruction</article-title><source>J Urol</source><year>2002</year><volume>167</volume><fpage>1513</fpage><lpage>1521</lpage><pub-id pub-id-type="pmid">11832780</pub-id></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schwinn</surname><given-names>DA</given-names></name></person-group><article-title>The role of alpha1-adrenergic receptor subtypes in lower urinary tract symptoms</article-title><source>BJU Int</source><year>2001</year><volume>88</volume><issue>Suppl 2</issue><fpage>27</fpage><lpage>34</lpage><pub-id pub-id-type="pmid">11589667</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malloy</surname><given-names>BJ</given-names></name><name><surname>Price</surname><given-names>DT</given-names></name><name><surname>Price</surname><given-names>RR</given-names></name><name><surname>Bienstock</surname><given-names>AM</given-names></name><name><surname>Dole</surname><given-names>MK</given-names></name><name><surname>Funk</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Alpha1-adrenergic receptor subtypes in human detrusor</article-title><source>J Urol</source><year>1998</year><volume>160</volume><issue>3 Pt 1</issue><fpage>937</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">9720591</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>Patient disposition. A total of 120 patients were screened and 118 were enrolled in this study. Ninety normotensive (NT) patients and 28 hypertensive (HT) patients were randomly assigned into the naftopidil 50 mg or naftopidil 75 mg group for 12-week, once-daily treatment. In the NT group, 83 patients completed the study. The main reason for study discontinuation was AEs (6 patients, 6.6%). In the HT group, 27 patients completed the study, and one discontinued because of loss during follow-up. AE, adverse event.</title></caption><graphic xlink:href="ymj-58-800-g001"/></fig><fig id="F2" orientation="portrait" position="float"><label>Fig. 2</label><caption><title>Comparison of the mean changes in BP from baseline value according to group. BP, blood pressure.</title></caption><graphic xlink:href="ymj-58-800-g002"/></fig><fig id="F3" orientation="portrait" position="float"><label>Fig. 3</label><caption><title>Change in efficacy parameters from baseline to each visit in the ITT population. IPSS, international prostate symptom score; SD, standard deviation; QoL, quality of life; Qmax, maximum urinary flow rate; ITT, intention to treat.</title></caption><graphic xlink:href="ymj-58-800-g003"/></fig><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Patient Demographics and Baseline Characteristics</title></caption><alternatives><graphic xlink:href="ymj-58-800-i001"/><table frame="hsides" rules="rows"><col width="20%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="2" colspan="1" style="background-color:rgb(230,231,232)"/><th valign="top" align="center" rowspan="1" colspan="2" style="background-color:rgb(230,231,232)">Normotension</th><th valign="top" align="center" rowspan="1" colspan="2" style="background-color:rgb(230,231,232)">Hypertension</th><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/></tr><tr><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Group 1<break/>
(naftopidil 50 mg)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Group 2<break/>
(naftopidil 75 mg)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Group 3<break/>
(naftopidil 50 mg)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Group 4<break/>
(naftopidil 75 mg)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"><italic>p</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">No. of patients</td><td valign="top" align="center" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">51</td><td valign="top" align="center" rowspan="1" colspan="1">12</td><td valign="top" align="center" rowspan="1" colspan="1">16</td><td valign="top" align="center" rowspan="1" colspan="1">-</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Mean (SD)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Age, yr</td><td valign="top" align="center" rowspan="1" colspan="1">65.5 (7.0)</td><td valign="top" align="center" rowspan="1" colspan="1">67.2 (6.5)</td><td valign="top" align="center" rowspan="1" colspan="1">62.2 (4.3)</td><td valign="top" align="center" rowspan="1" colspan="1">64.1 (7.4)</td><td valign="top" align="right" rowspan="1" colspan="1">0.151</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;Height, cm</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">168.4 (4.2)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">166.9 (7.2)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">168.4 (4.2)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">170.7 (6.3)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.382</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Weight, kg</td><td valign="top" align="center" rowspan="1" colspan="1">65.6 (7.0)</td><td valign="top" align="center" rowspan="1" colspan="1">67.8 (11)</td><td valign="top" align="center" rowspan="1" colspan="1">69.2 (6.9)</td><td valign="top" align="center" rowspan="1" colspan="1">70.5 (10.2)</td><td valign="top" align="right" rowspan="1" colspan="1">0.548</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;SBP, mm Hg</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">123.1 (10.1)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">124.9 (12.4)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">144.4 (21.0)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">145.3 (6.6)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;DBP, mmHg</td><td valign="top" align="center" rowspan="1" colspan="1">78.1 (6.5)</td><td valign="top" align="center" rowspan="1" colspan="1">77.1 (9.7)</td><td valign="top" align="center" rowspan="1" colspan="1">4.0 (3.0)</td><td valign="top" align="center" rowspan="1" colspan="1">93.5 (2.8)</td><td valign="top" align="right" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;Prostate volume, mL</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">30.4 (9.9)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">31.9 (8.4)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">7.5 (7.3)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">35.0 (10.6)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.394</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;PSA, ng/mL</td><td valign="top" align="center" rowspan="1" colspan="1">1.5 (1.1)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 (2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">1.3 (1.3)</td><td valign="top" align="center" rowspan="1" colspan="1">1.9 (1.7)</td><td valign="top" align="right" rowspan="1" colspan="1">0.703</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;IPSS (baseline)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Total</td><td valign="top" align="center" rowspan="1" colspan="1">18.8 (5.2)</td><td valign="top" align="center" rowspan="1" colspan="1">19.8 (6.5)</td><td valign="top" align="center" rowspan="1" colspan="1">17.4 (5.6)</td><td valign="top" align="center" rowspan="1" colspan="1">17.5 (3.1)</td><td valign="top" align="right" rowspan="1" colspan="1">0.595</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;&#x02003;Obstructive subscore</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">13.3 (4.3)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">13.5 (5.1)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">12.1 (4.2)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">12.2 (3.9)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.822</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Irritative subscore</td><td valign="top" align="center" rowspan="1" colspan="1">5.3 (2.2)</td><td valign="top" align="center" rowspan="1" colspan="1">6.3 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">5.2 (3.0)</td><td valign="top" align="center" rowspan="1" colspan="1">5.3 (1.9)</td><td valign="top" align="right" rowspan="1" colspan="1">0.425</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;&#x02003;QoL score</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">4.1 (0.7)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">4.5 (0.7)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">4.0 (0.8)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">4.2 (0.8)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.169</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">&#x02003;Qmax, mL/sec</td><td valign="top" align="center" rowspan="1" colspan="1">11.7 (2.8)</td><td valign="top" align="center" rowspan="1" colspan="1">10.8 (2.7)</td><td valign="top" align="center" rowspan="1" colspan="1">11.6 (3.3)</td><td valign="top" align="center" rowspan="1" colspan="1">9.6 (3.0)</td><td valign="top" align="right" rowspan="1" colspan="1">0.260</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;PVR, mL</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">26.1 (27.5)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">30.7 (38.3)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">20.0 (19.7)</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">44.2 (55.6)</td><td valign="top" align="right" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0.532</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Race (%)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;Asian</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">100</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">100</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">100</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">100</td><td valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">-</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>SD, standard deviation; SBP, systolic blood pressure; DBP, diastolic blood pressure; PSA, prostate specific antigen; IPSS, international prostate symptom score; QoL, quality of life; Qmax, maximum urinary flow rate; PVR, post-void residual urine volume.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Summary of Adverse Events<sup>*</sup></title></caption><alternatives><graphic xlink:href="ymj-58-800-i002"/><table frame="hsides" rules="rows"><col width="40%" span="1"/><col width="30%" span="1"/><col width="30%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Naftopidil 50 mg (n=51)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Naftopidil 75 mg (n=67)</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Dizziness, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">2 (3.9)</td><td valign="middle" align="center" rowspan="1" colspan="1">1 (1.4)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Orthostatic hypotension, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Syncope, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Headache, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Retrograde ejaculation, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Insomnia, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Chest pain, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Asthenia, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">Flu-like symptom, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">GI trouble, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">2 (3.9)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">1 (1.4)</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p><sup>*</sup>The safety population comprised all subjects who were randomized and received at least one dose of the study medication.</p></fn></table-wrap-foot></table-wrap><table-wrap id="T3" orientation="portrait" position="float"><label>Table 3</label><caption><title>Results of the BSW Questionnaire</title></caption><alternatives><graphic xlink:href="ymj-58-800-i003"/><table frame="hsides" rules="rows"><col width="48%" span="1"/><col width="26%" span="1"/><col width="26%" span="1"/><thead><tr><th valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Naftopidil 50 mg group (n=46)</th><th valign="top" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">Naftopidil 75 mg group (n=64)</th></tr></thead><tbody><tr><td valign="middle" align="left" rowspan="1" colspan="1">Subscales, n (%)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;Patient perception of treatment benefit (BSW-1)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;No benefit</td><td valign="middle" align="center" rowspan="1" colspan="1">7 (15.2)</td><td valign="middle" align="center" rowspan="1" colspan="1">14 (21.9)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;&#x02003;Little benefit</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">0 (0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Much benefit</td><td valign="middle" align="center" rowspan="1" colspan="1">39 (84.8)</td><td valign="middle" align="center" rowspan="1" colspan="1">50 (78.1)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;Patient satisfaction with treatment (BSW-2)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Dissatisfied</td><td valign="middle" align="center" rowspan="1" colspan="1">6 (13.0)</td><td valign="middle" align="center" rowspan="1" colspan="1">15 (23.4)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;&#x02003;Satisfied</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">40 (87.0)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">49 (76.6)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;Patient willingness to continue with treatment (BSW-3)</td><td valign="middle" align="center" rowspan="1" colspan="1"/><td valign="middle" align="center" rowspan="1" colspan="1"/></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">&#x02003;&#x02003;Unwilling</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">2 (4.3)</td><td valign="middle" align="center" rowspan="1" colspan="1" style="background-color:rgb(230,231,232)">9 (14.0)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">&#x02003;&#x02003;Willing</td><td valign="middle" align="center" rowspan="1" colspan="1">44&#x000a0;(95.7)</td><td valign="middle" align="center" rowspan="1" colspan="1">55&#x000a0;(86.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn><p>BSW, benefit, satisfaction with treatment, and willingness to continue treatment.</p></fn></table-wrap-foot></table-wrap></floats-group></article>